BioLineRx responds to rumors, cooling off its share price
Speculation about its new anti-schizophrenia drug fed 90% spike; company officials state that they have no new information.
Responding to speculation about the effectiveness of its experimental anti-schizophrenia drug that nearly doubled the company's share price, officials of BioLineRx announced Sunday they had no information about a recent clinical trial on the drug. The announcement sent shares of BioLineRx plunging 9.1% on trading volume of NIS 11.5 million, five times the normal rate.
Like us on Facebook and get articles directly in your news feed